Insilico Biotechnology AG opens subsidiary in Boston

27 February 2020

Stuttgart -- Insilico Biotechnology AG announces the opening of their first subsidiary in the United States, located in Boston, MA. The foundation of Insilico Biotechnology Corporation is an important next step to develop Insilico’s business in the highly relevant US biopharmaceutical market and will strengthen the company’s relationship with its customers in the US.

The Boston subsidiary´s prime location within the largest biopharmaceutical hub in the US provides access to a significant number of biopharmaceutical companies located within the east coast. The US market comprises about a third of the estimated 270 billion - dollar global biopharmaceutical market, and from this Insilico recognizes enormous growth opportunities for implementing its digital solutions for next generation smart biomanufacturing. In addition to developing the US business, Insilico Biotechnology Corp. will provide consulting and services for existing customers. With a team of account managers and application scientists, Insilico will be able to provide direct and onsite support for our customers who use the Insilico Technology Platform for predictive biomanufacturing.

Klaus Mauch, CEO of Insilico, explains “Following the opening of the representative office in Singapore, the foundation of the Boston subsidiary is a strategic step to achieve our vision of serving the global biopharmaceutical market as the leading provider of predictive solutions for smart biofactories“. Brett Lepore, the newly appointed president of Insilico Biotechnology Corp., adds “I am extremely happy about being able to directly contribute to our customers' successful digital transformation with Insilico as their partner. I am absolutely positive that this is the right time and that Boston is exactly the right place.“

About Insilico
Insilico Biotechnology AG develops and delivers predictive Digital Twins to advance biopharmaceutical process development and manufacturing. Insilico Digital Twins of cell culture processes lead to superior productivity, product quality and process robustness. Groundbreaking predictive power is achieved by exploiting process data using artificial intelligence and biochemical networks. As a result, Insilico’s unique approach substantially reduces experimental effort, costs of goods and time to market. Leading biopharmaceutical companies worldwide use Insilico Digital Twins for cell line development, media design and process control. Founded in 2001, Insilico Biotechnology is a privately held company based in Stuttgart, Germany.

Contact
Caroline Shafik
Public Relations Manager
Insilico Biotechnology AG
press@insilico-biotechnology.com

Back to news